Ribavirin
Ribavirin is a pharmaceutical drug with 413 clinical trials. Currently 4 active trials ongoing. Historical success rate of 87.1%.
Success Metrics
Based on 318 completed trials
Phase Distribution
Phase Distribution
32
Early Stage
150
Mid Stage
179
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
82.6%
318 of 385 finished
17.4%
67 ended early
4
trials recruiting
413
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir
Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected Patients
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
Clinical Trials (413)
Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir
Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected Patients
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
Assessing Antiviral Treatments in Early Symptomatic RSV
Ribavirin for Hemorrhagic Fever With Renal Syndrome
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
LAssa Fever Adjunct Treatment With DEXamethasone
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 413